Introduction of a new physical examination procedure for the differentiation of acromioclavicular joint lesions and subacromial impingement.

OBJECTIVE: To present a new physical examination procedure that may assist in differentiating acromioclavicular joint lesions from subacromial impingement lesions. DISCUSSION: The acromioclavicularjoint differential test is performed by applying downward pressure over the lateral one third of the clavicle while passively inducing slight' adduction, external rotation, and forced forward flexion to the humerus while the patient is in the seated position. Although similar mechanisms have been described, the acromioclavicular joint differential test is a new, previously unreported examination procedure. CONCLUSION: This article describes a new test to differentiate between acromioclavicular joint lesions and subacromial impingement. On the basis of its mechanism, the acromioclavicular joint differential test may provide the examiner with an additional tool in the differential diagnosis of acromioclavicularjoint lesions and subacromial impingement in the patient with shoulder pain. Although this test has been used by the author in a clinical setting, validation data are not yet available.

[The bioequivalence of a new amitriptyline tablet formulation in comparison with a reference preparation]. / Untersuchungen zur Bioäquivalenz einer neuen Amitriptylin-Tablettenformulierung im Vergleich zu einer Referenzzubereitung.

An investigation of the bioequivalence of a new tablet formulation (amitriptylin 25 von ct) with 28.3 mg amitriptyline hydrochloride (CAS 549-18-8) was performed in a two-way cross-over study with 18 subjects. The relative bioavailability with respect to a reference preparation for AUC related to amitriptyline (CAS 50-48-6) was 99.3% and for Cmax 100.4%. A positive decision for bioequivalence derived from the usual confidence intervals for both parameters related to amitriptyline and the metabolite nortriptyline (CAS 72-69-5), respectively tmax showed no difference. The new formulation was bioequivalent to the reference.

[Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation]. / Untersuchungen zur Bioäquivalenz einer neuen Isosorbiddinitrat-Tablettenformulierung im Vergleich zu einer Referenzformulierung.

An investigation in the bioequivalence of a new tablet formulation with 5 mg isosorbide dinitrate (CAS 87-33-2, ISDN 5 von ct) was performed in a two-way cross-over study with 18 subjects. The relative bioavailability with respect to a reference preparation for AUC related to isosorbide dinitrate was 107.5% and for Cmax 112.5%. A positive decision for bioequivalence derived from the usual confidence intervals for both parameters related to isosorbide dinitrate and the metabolites isosorbide-2-nitrate and isosorbide-5-nitrate, respectively. The difference in tmax showed no clinical relevance. The new formulation was bioequivalent to the reference.

[The bioequivalence of a new allopurinol tablet formulation in comparison to a reference formulation]. / Untersuchungen zur Bioäquivalenz einer neuen Allopurinol-Tablettenformulierung im Vergleich zu einer Referenzformulierung.

An investigation of the bioequivalence of a new allopurinol formulation with 300 mg allopurinol (CAS 315-30-0, allo 300 von ct) was performed in a two-way cross-over study with 18 subjects. The relative bioavailability with respect to a reference preparation for AUC related to oxipurinol was 98.1% and for Cmax 91.7%. A positive decision for bioequivalence derived from the usual confidence intervals for both parameters related to allopurinol and the metabolite oxipurinol, respectively, tmax showed no difference regarding oxipurinol. The new formulation was bioequivalent to the reference.